MXPA04001372A - Metodo para el tratamiento del insomnio primario. - Google Patents

Metodo para el tratamiento del insomnio primario.

Info

Publication number
MXPA04001372A
MXPA04001372A MXPA04001372A MXPA04001372A MXPA04001372A MX PA04001372 A MXPA04001372 A MX PA04001372A MX PA04001372 A MXPA04001372 A MX PA04001372A MX PA04001372 A MXPA04001372 A MX PA04001372A MX PA04001372 A MXPA04001372 A MX PA04001372A
Authority
MX
Mexico
Prior art keywords
melatonin
sleep
medicament
patients
agonists
Prior art date
Application number
MXPA04001372A
Other languages
English (en)
Spanish (es)
Inventor
Zisapel Nava
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11075696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA04001372(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of MXPA04001372A publication Critical patent/MXPA04001372A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
MXPA04001372A 2001-08-14 2002-08-12 Metodo para el tratamiento del insomnio primario. MXPA04001372A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL144900A IL144900A (en) 2001-08-14 2001-08-14 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
PCT/IL2002/000662 WO2003015690A2 (en) 2001-08-14 2002-08-12 Method for treating primary insomnia

Publications (1)

Publication Number Publication Date
MXPA04001372A true MXPA04001372A (es) 2005-06-06

Family

ID=11075696

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001372A MXPA04001372A (es) 2001-08-14 2002-08-12 Metodo para el tratamiento del insomnio primario.

Country Status (35)

Country Link
US (1) US8962024B2 (OSRAM)
EP (2) EP3103443B1 (OSRAM)
JP (1) JP2005501095A (OSRAM)
KR (1) KR20040032917A (OSRAM)
CN (1) CN100453078C (OSRAM)
AR (1) AR034975A1 (OSRAM)
AU (1) AU2002326114C1 (OSRAM)
BR (1) BR0211855A (OSRAM)
CA (1) CA2454699C (OSRAM)
CL (1) CL2002001701A1 (OSRAM)
CR (1) CR7271A (OSRAM)
CY (2) CY1118924T1 (OSRAM)
DK (2) DK1441702T3 (OSRAM)
EA (1) EA200400302A1 (OSRAM)
ES (2) ES2626591T3 (OSRAM)
GT (1) GT200200164A (OSRAM)
HU (1) HU230786B1 (OSRAM)
IL (1) IL144900A (OSRAM)
IS (1) IS3004B (OSRAM)
JO (1) JO3446B1 (OSRAM)
LT (1) LT1441702T (OSRAM)
MX (1) MXPA04001372A (OSRAM)
NO (1) NO334788B2 (OSRAM)
NZ (1) NZ531318A (OSRAM)
PA (1) PA8552301A1 (OSRAM)
PE (1) PE20030331A1 (OSRAM)
PL (1) PL367872A1 (OSRAM)
PT (2) PT3103443T (OSRAM)
PY (1) PY0218122A (OSRAM)
RU (1) RU2560840C2 (OSRAM)
SI (1) SI1441702T1 (OSRAM)
UA (1) UA87262C2 (OSRAM)
UY (1) UY27401A1 (OSRAM)
WO (1) WO2003015690A2 (OSRAM)
ZA (1) ZA200402005B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
US20070088079A1 (en) * 2005-09-20 2007-04-19 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for sleep disorder
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US8940326B2 (en) 2007-03-19 2015-01-27 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
WO2008122102A1 (en) * 2007-04-05 2008-10-16 Iomedix Development International Srl Melatonin-based composition for improved sleep
US20080248106A1 (en) 2007-04-05 2008-10-09 Marvin Heuer Melatonin-based composition for improved sleep
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) * 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
MX386987B (es) 2016-10-31 2025-03-19 Neurim Pharma 1991 Mini-tabletas de melatonina y métodos de fabricación de las mismas.
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) 1964-03-24 Chioacyl
US2789118A (en) 1956-03-30 1957-04-16 American Cyanamid Co 16-alpha oxy-belta1, 4-pregnadienes
US2990401A (en) 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3048581A (en) 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3749712A (en) 1970-09-25 1973-07-31 Sigma Tau Ind Farmaceuti Triamcinolone acetonide esters and process for their preparation
SE378110B (OSRAM) 1972-05-19 1975-08-18 Bofors Ab
US3996359A (en) 1972-05-19 1976-12-07 Ab Bofors Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
SE378109B (OSRAM) 1972-05-19 1975-08-18 Bofors Ab
JPS6045513A (ja) * 1983-05-18 1985-03-12 モナシユ　ユニバ−シテイ 身体行動および機能の日周期の不調を軽減する薬剤
DE3466215D1 (en) * 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
US5151446A (en) 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5707652A (en) 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
US5591768A (en) * 1990-12-04 1997-01-07 State Of Oregan, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Methods for treating circadian rhythm phase disturbances
EP0518468B1 (en) * 1991-05-09 1999-06-30 Neurim Pharmaceuticals (1991) Limited Melatonin containing compositions
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
FR2680507B1 (fr) 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ATE141051T1 (de) * 1992-04-07 1996-08-15 Neurim Pharma 1991 Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
IL103411A (en) 1992-10-11 1996-11-14 Neurim Pharma 1991 Melatonin Controlled Pharmacy Preparation for the Correction of Melatonin Deficiency or Distortion in Melatonin in Human Plasma
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
CA2150703C (en) 1992-12-17 2002-01-08 Pfizer Limited Substituted pyrazoles
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
ES2128544T3 (es) 1992-12-17 1999-05-16 Pfizer Pirrolopirimidinas como antagonistas del crf.
US5712303A (en) 1992-12-17 1998-01-27 Pfizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
AU7550994A (en) 1993-07-26 1995-02-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Sustained release oral compositions containing melatonin
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
US5688520A (en) * 1995-03-29 1997-11-18 Minnesota Mining And Manufacturing Company Transmucosal delivery of melatonin for prevention of migraine
EP0748627A3 (en) 1995-06-14 1997-05-21 Lilly Co Eli Melatonin agonists for the treatment of benign forms of hyperplasia of the prostate
NO981489L (no) * 1995-10-03 1998-05-22 Interneuron Pharma Blandinger av melatonin og analgetika samt anvendelser derav
US6274604B1 (en) * 1996-07-17 2001-08-14 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
US5776969A (en) 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US5826408A (en) * 1997-05-08 1998-10-27 Riverwood International Corporation Rotary flap tucker for a cartoning machine
US6472421B1 (en) * 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
HK1052655A1 (zh) * 2000-01-05 2003-09-26 纽里姆药品(1991)有限公司 用於治療對抗高血壓藥的抗藥性和相關病症的方法和製劑
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6703412B1 (en) * 2002-09-27 2004-03-09 Holly A. Rosenthal Method of treating sleeplessness with melatonin on an acute basis
JP2014533981A (ja) 2011-09-27 2014-12-18 アイビス・メディカル・インコーポレーテッド 胃内インプラントデバイス

Also Published As

Publication number Publication date
IL144900A0 (en) 2002-06-30
US20040248966A1 (en) 2004-12-09
WO2003015690B1 (en) 2004-03-11
UY27401A1 (es) 2003-02-28
GT200200164A (es) 2003-09-26
US8962024B2 (en) 2015-02-24
EP3103443A1 (en) 2016-12-14
WO2003015690A3 (en) 2003-09-25
CY1118924T1 (el) 2018-01-10
HK1066161A1 (zh) 2005-03-18
CL2002001701A1 (es) 2010-06-25
HU230786B1 (en) 2018-05-02
IS7136A (is) 2004-01-30
NZ531318A (en) 2005-08-26
PY0218122A (es) 2004-03-01
IS3004B (is) 2018-09-15
JP2005501095A (ja) 2005-01-13
EP1441702B1 (en) 2017-05-10
DK1441702T3 (en) 2017-06-06
EP1441702A4 (en) 2007-09-26
JO3446B1 (ar) 2020-07-05
EP3103443B1 (en) 2021-06-30
PA8552301A1 (es) 2003-06-30
NO20040087L (no) 2004-02-19
PT1441702T (pt) 2017-06-02
CN100453078C (zh) 2009-01-21
CA2454699C (en) 2012-03-27
DK3103443T3 (da) 2021-08-30
CA2454699A1 (en) 2003-02-27
AU2002326114C1 (en) 2019-03-21
CR7271A (es) 2004-05-17
ES2882584T3 (es) 2021-12-02
LT1441702T (lt) 2017-06-12
ZA200402005B (en) 2005-07-27
KR20040032917A (ko) 2004-04-17
NO334788B1 (no) 2014-05-26
EP1441702A2 (en) 2004-08-04
HUP0401042A2 (hu) 2004-08-30
AU2002326114B2 (en) 2007-03-08
RU2560840C2 (ru) 2015-08-20
SI1441702T1 (sl) 2017-08-31
PE20030331A1 (es) 2003-06-27
HUP0401042A3 (en) 2009-07-28
BR0211855A (pt) 2004-09-21
ES2626591T3 (es) 2017-07-25
IL144900A (en) 2013-12-31
RU2011131532A (ru) 2013-03-27
AR034975A1 (es) 2004-03-24
WO2003015690A2 (en) 2003-02-27
UA87262C2 (uk) 2009-07-10
CY1124763T1 (el) 2022-07-22
NO334788B2 (no) 2014-05-26
AU2002326114A1 (en) 2003-03-03
CN1541092A (zh) 2004-10-27
PL367872A1 (en) 2005-03-07
PT3103443T (pt) 2021-08-12
EA200400302A1 (ru) 2004-10-28

Similar Documents

Publication Publication Date Title
Benca et al. Sleep and mood disorders
Gillin et al. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial
Kornstein et al. Low-dose sertraline in the treatment of moderate-to-severe premenstrual syndrome: efficacy of 3 dosing strategies
JP6480050B2 (ja) メラトニンアゴニスト治療
JP3686063B2 (ja) 睡眠障害の改善作用を有する健康補助食品
ES2882584T3 (es) Procedimiento para tratar el insomnio primario
US20200323823A1 (en) Methods for the treatment of depression
WO2023114529A2 (en) Pharmacoactive formulations for delivery of psychedelic compounds
TWI324935B (OSRAM)
HK1066161B (en) Method for treating primary insomnia
AU2013214223B2 (en) (1r,4r)-6'-Fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro-[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for treating fibromyalgia and chronic fatigue syndrome
TW202416952A (zh) 治療cns病症之方法
Kowshihan et al. Effectiveness of Paroxetine in Controlling Anxiety during Tooth Preparation—A Prospective Trial
JP2026504239A (ja) 不安および関連状態を治療する方法
JP2024023688A (ja) タシメルテオンを用いる障害の治療
Delbressine et al. P. 1.034 In vivo study in humans on disposition of the enantiomers and metabolites of mirtazapine
PATEL et al. SLEEP DISORDERS AND MEDICATIONS
Dragheim et al. P. 2. c. 024 A double-blind, randomised, placebocontrolled, relapse-prevention study with Lu AA21004 in patients with major depressive disorder
de la Gándara P. 1.032 Premenstrual dysphoric disorder: Long-term treatment and discontinuation of fluoxetine 20 MG
WO2004037238A1 (en) New uses of deramciclane
Conte et al. P. 1.031 The role of clonidine in the treatment of manic episodes
AT507103A2 (de) Mittel zur unterstützung bei liebeskummer und trennungsschmerz